Semaglutide vs Tirzepatide

Two leading GLP-1 based treatments for weight loss and metabolic health

View Comparison

Quick Summary

Key Insight: Semaglutide is a GLP-1 receptor agonist, while Tirzepatide is a dual GIP/GLP-1 receptor agonist. Both are highly effective, but Tirzepatide shows slightly greater average weight loss in clinical studies.

Despite differences in mechanism, both medications belong to the modern class of injectable metabolic therapies.

Semaglutide Treatment Option

Semaglutide remains one of the most widely used and clinically validated GLP-1 medications worldwide.

Explore Semaglutide Guide

Side-by-Side Comparison

Feature Semaglutide ⭐ Core Focus Tirzepatide
Drug Class GLP-1 receptor agonist Dual GIP + GLP-1 agonist
Weight Loss 10–15% 15–22%
Diabetes Control Strong Very strong
Appetite Suppression High Very high
Administration Weekly injection Weekly injection
Mechanism GLP-1 receptor activation GLP-1 + GIP receptor activation
Clinical Maturity Highly established Newer but rapidly growing
Availability Widely available Limited in some regions

Medical Verdict

Tirzepatide shows slightly higher average weight loss in clinical trials, but Semaglutide remains the most established, widely used and clinically validated GLP-1 medication globally.

For long-term clinical adoption and accessibility, Semaglutide remains the reference standard in GLP-1 therapy.

View Semaglutide Dosage Guide

Start with Semaglutide

Explore treatment plans, dosing schedules, and expected results.

Cost & Availability Side Effects

FAQ

Tirzepatide shows slightly higher average weight loss in clinical trials, but both are highly effective.

Both medications have similar safety profiles with gastrointestinal side effects being most common.

Semaglutide has longer real-world usage and broader global adoption.

Semaglutide Guides